Recent Updates
Recently added Catalysts
OPCH Positive Sentiment Score: 72/100

OPTION CARE HEALTH ANNOUNCES PRELIMINARY FOURTH QUARTER & FULL YEAR 2025 FINANCIAL RESULTS AND PRELIMINARY FINANCIAL GUIDANCE FOR FULL YEAR 2026 BANNOCKBURN, IL.

Key Takeaway: Option Care Health has announced its preliminary fourth quarter and full year 2025 financial results, along with preliminary guidance for 2026. The company expects to provide more detailed guidance during its upcoming earnings call. Additionally, the company's board has approved an increase in the share repurchase program from $500 million to $1 billion, emphasizing its commitment to returning value to shareholders. Investor engagement will continue with a presentation at the J.P. Morgan Healthcare Conference in January.

Market Sentiment Analysis

POSITIVE FACTORS

  • The company reported preliminary financial results indicating growth expectations.
  • An expanded share repurchase program demonstrates confidence in the company's value.
  • Engagement at the upcoming J.P. Morgan Healthcare Conference showcases proactive investor relations.

Full Press Release Details

OPTION CARE HEALTH ANNOUNCES PRELIMINARY FOURTH
QUARTER & FULL YEAR 2025 FINANCIAL RESULTS AND PRELIMINARY FINANCIAL GUIDANCE FOR FULL YEAR 2026
IL., January 12, 2026 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq:
OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today preliminary unaudited
financial results for the fourth quarter and full year ended December 31, 2025, and preliminary financial guidance for the full
(Year-over-year comparisons unless otherwise noted; Growth comparisons
versus midpoint of range)
Fourth Quarter 2025 Preliminary Expected Results
Full Year 2025 Preliminary Expected Results
Full Year 2026 Preliminary Financial Guidance
The Company expects to provide further information
regarding its full year 2026 financial guidance on its fourth quarter earnings call in February.
Expanded Share Repurchase Program Authorization
On January 9, 2026, the Company's Board of Directors approved
an increase to its 2025 share repurchase program authorization, from $500 million to $1.0 billion. This program has no specified expiration
date. Shares may be repurchased under the program through open market purchases, privately negotiated transactions, or other structured
share repurchase programs. The timing and actual amount of shares repurchased will depend upon a variety of factors, including market
conditions, regulatory requirements, and other corporate considerations, as determined by the Company's management.
Under the 2025 share repurchase program, the Company repurchased approximately
$95 million of shares during the fourth quarter of 2025 and approximately $307 million during the full year 2025. As of December 31,
2025, the 2025 share repurchase program had purchase capacity of approximately $193 million. The expanded authorization added an additional
$500 million to the capacity.
Investor Conference Presentation
The Company will be participating in the 44th Annual J.P. Morgan Healthcare
Conference, including a Company presentation at 10:30 a.m. P.T. on Tuesday, January 13, 2026. The presentation, including the presentation
materials, can be accessed via live audio webcast that will be available online at investors.optioncarehealth.com.
About Option Care Health
Option Care Health is the nation's largest independent provider
of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately
to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise
and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more,
please visit our website at optioncarehealth.com.
Senior Vice President, Corporate Controller
Forward-Looking Statements - Safe Harbor
This press release contains "forward-looking statements"
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements
can be identified by words such as: "anticipate," "intend," "plan," "believe," "project,"
"estimate," "expect," "may," "should," "will" and similar references to future
periods. Examples of forward-looking statements include, among others, statements the Company may make regarding future revenues, future
earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects
of any of the foregoing on its future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances
of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the
future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial
condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's
actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others,
the following: changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care
organizations and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing
research, development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity
to its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. For a detailed
discussion of the risk factors that could affect its actual results, please refer to the risk factors identified in the Company's
SEC reports as filed with the SEC.
Any forward-looking statement made by the Company in this press release
is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no
obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.
Preliminary Unaudited Financial Data
The preliminary financial information included in this press release
is subject to completion of the Company's year-end close procedures and further financial review. The Company has provided ranges,
rather than specific amounts, because these results are preliminary and subject to change. Actual results may differ from these estimates
as a result of the completion of the Company's year-end closing procedures, review adjustments and other developments that may
arise between now and the time such financial information for the period is finalized. As a result, these estimates are preliminary,
may change and constitute forward-looking information and, as a result, are subject to risks and uncertainties. These preliminary estimates
should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting
principles ("GAAP"), and they should not be viewed as indicative of the Company's results for any future period. The
Company's independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect
to these estimated financial results and, accordingly, does not express an opinion or any other form of assurance with respect to these
preliminary estimates.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with
generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted
earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial
performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance
measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the
Company's liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may
not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted
net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment
of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net
income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment
of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents Adjusted net income
divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses,
the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant expenses, professional
fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential
accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures
provide useful supplemental information regarding the performance of Option Care Health's business operations and facilitate comparisons
to the Company's historical operating results. The Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted
diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be practicable due to the uncertainty
regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the
most comparable GAAP financial measure are set forth below.
OPTION CARE HEALTH, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN MILLIONS, EXCEPT PER SHARE AMOUNTS)
Three Months Ended December 31, 2025 Year Ended December 31, 2025
Low High Low High
Net income $ 59.1 $ 62.4 $ 208.2 $ 211.5
Interest expense, net 12.8 12.8 54.6 54.6
Income tax expense 23.3 22.2 75.6 74.5
Depreciation and amortization expense 17.1 17.1 67.5 67.5
EBITDA 112.3 114.5 405.9 408.1
EBITDA adjustments
Stock-based incentive compensation 9.4 9.4 40.0 40.0
Loss on extinguishment of debt - - 4.7 4.7
Restructuring, acquisition, integration and other 2.1 3.9 18.4 20.2
Adjusted EBITDA $ 123.7 $ 127.7 $ 469.0 $ 473.0
Net income $ 59.1 $ 62.4 $ 208.2 $ 211.5
Intangible asset amortization expense 9.2 9.2 36.9 36.9
Stock-based incentive compensation 9.4 9.4 40.0 40.0
Loss on extinguishment of debt - - 4.7 4.7
Restructuring, acquisition, integration and other 2.1 3.9 18.4 20.2
Total pre-tax adjustments 20.6 22.4 100.0 101.8
Tax adjustments (1) (6.0 ) (5.9 ) (26.6 ) (26.5 )
Adjusted net income $ 73.8 $ 79.0 $ 281.6 $ 286.8
Earnings per share, diluted $ 0.37 $ 0.39 $ 1.27 $ 1.29
Adjusted earnings per share, diluted $ 0.46 $ 0.49 $ 1.72 $ 1.76
Weighted average common shares outstanding, diluted 159,833 159,833 163,365 163,365
(1) Tax adjustments for fourth quarter and full year 2025 includes
the estimated income tax effect on non-GAAP adjustments based on the expected effective tax rate

Frequently Asked Questions

What were Option Care Health's Q4 2025 results?

Option Care Health announced preliminary financial results for Q4 2025 but actual figures are subject to year-end adjustments.

What is the share repurchase program update?

On January 9, 2026, the repurchase program was increased to $1 billion, with $193 million remaining as of December 31, 2025.

When will detailed 2026 guidance be shared?

Further information on full year 2026 financial guidance will be provided during the earnings call in February.

What is the role of Option Care Health?

Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S.

How does the company define Adjusted measures?

Adjusted measures exclude certain expenses like amortization and restructuring costs for a clearer financial picture.

Last updated: Jan 12, 2026